Endometrial Cancer New FIGO Stage IA3 vs IIIA1 with Koji Matsuo

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Koji Matsuo to discuss new FIGO staging of endometrial cancer. Dr. Matsuo is a clinician-scientist in the area of gynecologic oncology in the United States. His research interest is population-based, heath service outcome research for gynecologic malignancies. Highlights: (1) Survival effect of adjuvant therapy differed between stage IA3 and IIIA1. (2) In new stage IA3 disease, omission of adjuvant therapy had comparable overall survival compared to combination chemotherapy and external beam radiotherapy or chemotherapy alone. (3) In stage IIIA1, omission of adjuvant therapy was associated with decreased overall survival compared to chemotherapy-based approach. (4) 5-year overall survival of adjuvant therapy omission group in new stage IA3 was nearly 90%. (5) These hypothesis-generating observation suggested that treatment de-escalation of well-staged stage IA3 may not adversely affect survival.